SCHEDULE: Viking Global Investors Boosts Oric Pharma Stake to 9.99%

Viking Global Investors LP and its affiliates report a 9.99% beneficial ownership stake in Oric Pharmaceuticals, Inc., including common stock and exercisable pre-funded warrants.

Summary

• Viking Global Investors LP and its affiliated entities, including Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Opportunities Drawdown GP LLC, Viking Global Opportunities Drawdown Portfolio GP LLC, and Viking Global Opportunities Drawdown (Aggregator) LP, along with individuals O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, collectively report beneficial ownership.
• The aggregate amount beneficially owned by the primary reporting persons is 8,729,345 shares of Oric Pharmaceuticals, Inc. Common Stock.
• This ownership represents 9.99% of the outstanding Common Stock, calculated based on 85,224,191 shares outstanding as of May 29, 2025, plus 2,156,645 shares currently purchasable via warrants.
• The beneficial ownership includes 6,572,700 shares of Common Stock directly owned by VGOP (4,312,800 shares) and VGOD (2,259,900 shares).
• It also includes 2,156,645 shares of Common Stock that VGOP (1,293,987 shares) and VGOD (862,658 shares) have the right to purchase upon exercise of pre-funded warrants, subject to a 9.99% beneficial ownership blocker.
• All reporting persons hold shared voting and shared dispositive power over their respective beneficially owned shares, with no sole voting or dispositive power reported.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook. It is a factual report of an investment stake.

Risks

• The terms of the pre-funded warrants include a 'Blocker' provision, preventing the exercise of warrants if it would result in the holder (together with affiliates and any Section 13(d) group members) beneficially owning more than 9.99% of the outstanding Common Stock immediately following exercise.
• The Blocker can be increased or decreased up to a maximum of 19.99% upon notice to the Issuer, but such changes are not effective until 61 days after notice is delivered.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Oric Pharmaceuticals, Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

This Schedule 13G filing indicates a significant passive investment by Viking Global Investors, a prominent investment firm, in Oric Pharmaceuticals, Inc., a company in the pharmaceutical sector. Such filings are common for institutional investors taking substantial, non-controlling stakes in publicly traded companies, reflecting their investment thesis rather than operational or strategic changes within the company itself.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor, Viking Global Investors, holds a substantial stake, which can be viewed as a vote of confidence or a stable large holder. The 'Blocker' provision on warrants limits immediate dilution from full warrant exercise by this holder.

Key Dates

Keywords

Oric Pharmaceuticals, Viking Global Investors, Schedule 13G, Beneficial Ownership, Common Stock, Pre-funded Warrants, Institutional Investor, Equity Stake, SEC Filing